FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966893415> ?p ?o ?g. }

• W1966893415 endingPage "1577" @default.
• W1966893415 startingPage "1577" @default.
• W1966893415 abstract "A high priority in vaccine research is the development of influenza vaccines that do not use embryonated eggs as the substrate for vaccine production.To determine the dose-related safety, immunogenicity, and protective efficacy of an experimental trivalent influenza virus hemagglutinin (rHA0) vaccine produced in insect cells using recombinant baculoviruses.Randomized, double-blind, placebo-controlled clinical trial at 3 US academic medical centers during the 2004-2005 influenza season among 460 healthy adults without high-risk indications for influenza vaccine.Participants were randomly assigned to receive a single injection of saline placebo (n = 154); 75 microg of an rHA0 vaccine containing 15 microg of hemagglutinin from influenza A/New Caledonia/20/99(H1N1) and influenza B/Jiangsu/10/03 virus and 45 microg of hemagglutinin from influenza A/Wyoming/3/03(H3N2) virus (n = 153); or 135 microg of rHA0 containing 45 microg of hemagglutinin each from all 3 components (n = 153). Serum samples were taken before and 30 days following immunization.Primary safety end points were the rates and severity of solicited and unsolicited adverse events. Primary immunogenicity end points were the rates of 4-fold or greater increases in serum hemagglutinin inhibition antibody to each of the 3 vaccine strains before and 28 days after inoculation. The prespecified primary efficacy end point was culture-documented influenza illness, defined as development of influenza-like illness associated with influenza virus on a nasopharyngeal swab.Rates of local and systemic adverse effects were low, and the rates of systemic adverse effects were not different in either vaccine group than in the placebo group. Hemagglutinin inhibition antibody responses to the H1 component were seen in 3% of placebo, 51% of 75-microg vaccine, and 67% of 135-microg vaccine recipients, while responses to B were seen in 4% of placebo, 65% of 75-microg vaccine, and 92% of 135-microg vaccine recipients. Responses to the H3 component occurred in 11% of placebo, 81% of 75-microg vaccine, and 77% of 135-microg vaccine recipients. Influenza infections in the study population were due to influenza B and A(H3N2), and influenza A infections were A/California/7/2004-like viruses, an antigenically drifted strain. Seven cases of culture-confirmed CDC-defined influenza-like illness occurred in 153 placebo recipients (4.6%) compared with 2 cases (1.3%) in 150 recipients of 75 microg of vaccine, and 0 cases in recipients of 135 microg of vaccine.In this study, a trivalent rHA0 vaccine was safe and immunogenic in a healthy adult population. Preliminary evidence of protection against a drifted influenza A(H3N2) virus was obtained, but the sample size was small. Inclusion of a neuraminidase component did not appear to be required for protection.clinicaltrials.gov Identifier: NCT00328107." @default.
• W1966893415 created "2016-06-24" @default.
• W1966893415 creator A5010300227 @default.
• W1966893415 creator A5018742667 @default.
• W1966893415 creator A5021523540 @default.
• W1966893415 creator A5023641721 @default.
• W1966893415 creator A5037028100 @default.
• W1966893415 creator A5052964435 @default.
• W1966893415 creator A5067329211 @default.
• W1966893415 creator A5071721061 @default.
• W1966893415 creator A5076981456 @default.
• W1966893415 creator A5083732628 @default.
• W1966893415 date "2007-04-11" @default.
• W1966893415 modified "2023-10-14" @default.
• W1966893415 title "Safety and Immunogenicity of a Baculovirus-Expressed Hemagglutinin Influenza Vaccine" @default.
• W1966893415 cites W1998015416 @default.
• W1966893415 cites W2025333144 @default.
• W1966893415 cites W2049342216 @default.
• W1966893415 cites W2082461885 @default.
• W1966893415 cites W2098137295 @default.
• W1966893415 cites W2111693224 @default.
• W1966893415 cites W2114711026 @default.
• W1966893415 cites W2114927707 @default.
• W1966893415 cites W2115037143 @default.
• W1966893415 cites W2144748417 @default.
• W1966893415 cites W2153564793 @default.
• W1966893415 cites W70314190 @default.
• W1966893415 doi "https://doi.org/10.1001/jama.297.14.1577" @default.
• W1966893415 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17426277" @default.
• W1966893415 hasPublicationYear "2007" @default.
• W1966893415 type Work @default.
• W1966893415 sameAs 1966893415 @default.
• W1966893415 citedByCount "161" @default.
• W1966893415 countsByYear W19668934152012 @default.
• W1966893415 countsByYear W19668934152013 @default.
• W1966893415 countsByYear W19668934152014 @default.
• W1966893415 countsByYear W19668934152015 @default.
• W1966893415 countsByYear W19668934152016 @default.
• W1966893415 countsByYear W19668934152017 @default.
• W1966893415 countsByYear W19668934152018 @default.
• W1966893415 countsByYear W19668934152019 @default.
• W1966893415 countsByYear W19668934152020 @default.
• W1966893415 countsByYear W19668934152021 @default.
• W1966893415 countsByYear W19668934152022 @default.
• W1966893415 countsByYear W19668934152023 @default.
• W1966893415 crossrefType "journal-article" @default.
• W1966893415 hasAuthorship W1966893415A5010300227 @default.
• W1966893415 hasAuthorship W1966893415A5018742667 @default.
• W1966893415 hasAuthorship W1966893415A5021523540 @default.
• W1966893415 hasAuthorship W1966893415A5023641721 @default.
• W1966893415 hasAuthorship W1966893415A5037028100 @default.
• W1966893415 hasAuthorship W1966893415A5052964435 @default.
• W1966893415 hasAuthorship W1966893415A5067329211 @default.
• W1966893415 hasAuthorship W1966893415A5071721061 @default.
• W1966893415 hasAuthorship W1966893415A5076981456 @default.
• W1966893415 hasAuthorship W1966893415A5083732628 @default.
• W1966893415 hasBestOaLocation W19668934151 @default.
• W1966893415 hasConcept C126322002 @default.
• W1966893415 hasConcept C142724271 @default.
• W1966893415 hasConcept C159047783 @default.
• W1966893415 hasConcept C159654299 @default.
• W1966893415 hasConcept C197934379 @default.
• W1966893415 hasConcept C203014093 @default.
• W1966893415 hasConcept C204787440 @default.
• W1966893415 hasConcept C22070199 @default.
• W1966893415 hasConcept C2522874641 @default.
• W1966893415 hasConcept C27081682 @default.
• W1966893415 hasConcept C2777546802 @default.
• W1966893415 hasConcept C2778692840 @default.
• W1966893415 hasConcept C2780689484 @default.
• W1966893415 hasConcept C2780868878 @default.
• W1966893415 hasConcept C2781416681 @default.
• W1966893415 hasConcept C2909469553 @default.
• W1966893415 hasConcept C2911126560 @default.
• W1966893415 hasConcept C71924100 @default.
• W1966893415 hasConceptScore W1966893415C126322002 @default.
• W1966893415 hasConceptScore W1966893415C142724271 @default.
• W1966893415 hasConceptScore W1966893415C159047783 @default.
• W1966893415 hasConceptScore W1966893415C159654299 @default.
• W1966893415 hasConceptScore W1966893415C197934379 @default.
• W1966893415 hasConceptScore W1966893415C203014093 @default.
• W1966893415 hasConceptScore W1966893415C204787440 @default.
• W1966893415 hasConceptScore W1966893415C22070199 @default.
• W1966893415 hasConceptScore W1966893415C2522874641 @default.
• W1966893415 hasConceptScore W1966893415C27081682 @default.
• W1966893415 hasConceptScore W1966893415C2777546802 @default.
• W1966893415 hasConceptScore W1966893415C2778692840 @default.
• W1966893415 hasConceptScore W1966893415C2780689484 @default.
• W1966893415 hasConceptScore W1966893415C2780868878 @default.
• W1966893415 hasConceptScore W1966893415C2781416681 @default.
• W1966893415 hasConceptScore W1966893415C2909469553 @default.
• W1966893415 hasConceptScore W1966893415C2911126560 @default.
• W1966893415 hasConceptScore W1966893415C71924100 @default.
• W1966893415 hasIssue "14" @default.
• W1966893415 hasLocation W19668934151 @default.
• W1966893415 hasLocation W19668934152 @default.
• W1966893415 hasOpenAccess W1966893415 @default.
• W1966893415 hasPrimaryLocation W19668934151 @default.

• next